Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Comoglio

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Biorxiv : the Preprint Server for Biology|June 6, 2025
<i>In vivo</i> CRISPR screening identifies <i>NF1/RASA1/TP53</i> co-mutations and downstream MEK signaling as a common key mechanism of sinonasal tumorigenesisKenny Vu, Sreenivasulu Gunti, Ramya Viswanathan, et al.
Nature Medicine|December 20, 2016
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemiaConstanze Schneider, Thomas Oellerich, Hanna-Mari Baldauf, et al.
Cancer Cell|March 4, 2022
The proteogenomic subtypes of acute myeloid leukemiaAshok Kumar Jayavelu, Sebastian Wolf, Florian Buettner, et al.
EMBO Molecular Medicine|August 12, 2018
Comparative proteomics reveals a diagnostic signature for pulmonary head-and-neck cancer metastasisHanibal Bohnenberger, Lars Kaderali, Philipp Ströbel, et al.
Blood|October 8, 2021
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphomaAnne C Wilke, Carmen Doebele, Alena Zindel, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Biorxiv : the Preprint Server for Biology|June 6, 2025
<i>In vivo</i> CRISPR screening identifies <i>NF1/RASA1/TP53</i> co-mutations and downstream MEK signaling as a common key mechanism of sinonasal tumorigenesisKenny Vu, Sreenivasulu Gunti, Ramya Viswanathan, et al.
Nature Medicine|December 20, 2016
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemiaConstanze Schneider, Thomas Oellerich, Hanna-Mari Baldauf, et al.
Cancer Cell|March 4, 2022
The proteogenomic subtypes of acute myeloid leukemiaAshok Kumar Jayavelu, Sebastian Wolf, Florian Buettner, et al.
EMBO Molecular Medicine|August 12, 2018
Comparative proteomics reveals a diagnostic signature for pulmonary head-and-neck cancer metastasisHanibal Bohnenberger, Lars Kaderali, Philipp Ströbel, et al.
Blood|October 8, 2021
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphomaAnne C Wilke, Carmen Doebele, Alena Zindel, et al.
Pageof 4